Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of “Hold” by Analysts

Certara, Inc. (NASDAQ:CERT) has been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $17.08.

A number of analysts have recently commented on CERT shares. Barclays dropped their target price on shares of Certara from $16.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 15th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Robert W. Baird decreased their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. KeyCorp dropped their price target on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th.

Certara Price Performance

CERT stock opened at $10.54 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. Certara has a 1 year low of $10.35 and a 1 year high of $19.87. The firm has a 50-day moving average of $11.58 and a 200 day moving average of $14.28. The company has a market cap of $1.70 billion, a P/E ratio of -27.03, a PEG ratio of 5.40 and a beta of 1.49.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. During the same period in the prior year, the company posted $0.10 EPS. The firm’s revenue was up 3.2% on a year-over-year basis. On average, sell-side analysts forecast that Certara will post 0.27 EPS for the current year.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by insiders.

Institutional Investors Weigh In On Certara

A number of hedge funds have recently added to or reduced their stakes in CERT. Blue Trust Inc. bought a new stake in shares of Certara in the second quarter worth $26,000. Innealta Capital LLC bought a new stake in shares of Certara during the 2nd quarter valued at about $36,000. Intech Investment Management LLC purchased a new stake in shares of Certara during the 2nd quarter valued at about $152,000. Algert Global LLC purchased a new position in shares of Certara in the second quarter worth approximately $156,000. Finally, MQS Management LLC bought a new stake in Certara during the second quarter valued at approximately $162,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.